Drugs / Cyclosporine
Cyclosporine
also known as
Cyclosporine A · CSA · Cyclosporin · ciclosporin · Restasis · Neoral · ciclosporin A · cyclosporin A · +55 more
Peptide targets ABCB1, ABCC2, CYP3A4, IL2, TGFB1 via inhibition / activation
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed dry eye syndrome 2 milestones | |||||
| Filed | China (NMPA) | — | dry eye syndrome | 2023-03-21 | “SHR8028 (cyclosporine ophthalmic solution) eye drops for the treatment of the signs and symptoms of dry eye disease was accepted by NMPA.” novaliq.com ↗ |
| Filed | US (FDA) | — | dry eye syndrome | 2017-12-27 | “the US FDA has accepted a New Drug Application (NDA), filed by its wholly owned subsidiary, for OTX-101 (cyclosporine A, ophthalmic solution) 0.09%” sunpharma.com ↗ |
| Filed vernal conjunctivitis 1 milestone | |||||
| Filed | US (FDA) | — | vernal conjunctivitis | 2020-10-26 | “The NDA submission for cyclosporine topical ophthalmic emulsion, 0.1% is supported by data from VEKTIS (NCT01751126)” santen.com ↗ |
| Approved Indication not stated 2 milestones | |||||
| Approved | EU (EMA) | Ikervis | — | 2015-03-19 | europa.eu ↗ |
| Approved | US (FDA) | SANDIMMUNE | — | 1983-11-14 | fda.gov ↗ |
Trials 365 · started per year
today
US approved 1983
EU approved 2015
2
1
2
4
2
5
3
14
5
7
8
19
18
16
14
12
14
17
16
12
11
15
6
6
10
10
8
28
21
8
11
6
13
14
19831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT07029204 | Aug 2025 → Jul 2026 overdue | alopecia areata | University of California, Davis | Recruiting | No outcome recorded |
| Phase 0 | NCT07239128 | May 2024 → Jun 2025 | dry eye syndrome | University of Seville | Completed | No outcome recorded |
| Phase 0 | NCT04812951 | Feb → Jun 2021 | — | Campus-Bio-Medico University | Completed | No outcome recorded |
| Phase 0 | NCT00378677 | Feb 2007 → ? | bronchiolitis obliterans syndrome | University Medical Center Groningen | Unknown | No outcome recorded |
| Phase 158 trials | ||||||
| Phase 1 | NCT07862114 | Oct 2026 → Jan 2027 expected | digestive system neoplasm | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07774325 | Sep → Oct 2026 expected | — | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 1 | NCT07565441 | May → Nov 2026 expected | autosomal dominant polycystic kidney disease | Jemincare | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07196449 | May → Jun 2025 overdue | — | Seoul National University Bundang Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06837259 | Mar → Jun 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06892756 | Mar → Jun 2025 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT06809608 | Feb → May 2025 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT06541678 | Dec 2024 → Mar 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06005714 | Aug → Oct 2023 | — | Shanghai Vinnerna Biosciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05573230 | Oct 2022 → Jan 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05202145 | Jan → Mar 2022 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05155007 | Dec 2021 → Feb 2022 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04849299 | Apr → May 2021 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04813653 | Apr 2021 → Mar 2025 | plasma cell myeloma, refractory plasma cell neoplasm | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT04788641 | Mar → Sep 2021 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04542252 | Nov → Dec 2020 | — | SymBio Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04532918 | Sep → Nov 2020 | chronic kidney disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05088174 | Sep → Oct 2020 | aplastic anemia | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05353101 | Jul 2020 → Jun 2021 | vernal keratoconjunctivitis | Second Affiliated Hospital of Nanchang University | Completed | No outcome recorded |
| Phase 1 | NCT04412785 | Jun 2020 → Oct 2021 | COVID-19 | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT04149678 | Oct → Nov 2019 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03768609 | Dec 2018 → Mar 2019 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT03750383 | Nov 2018 | respiratory syncytial virus infectious disease | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT05109390 | Jul → Oct 2018 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03801746 | Jul → Aug 2018 | — | Akebia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03466567 | Mar → Jul 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03419910 | Mar → May 2018 | psoriasis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03013933 | May 2017 → May 2022 | Hodgkins lymphoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT03095547 | May → Jul 2017 | invasive aspergillosis | F2G Ltd | Withdrawn | No outcome recorded |
| Phase 1 | NCT03136237 | Feb → Aug 2017 | hereditary angioedema | BioCryst Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02281370 | Nov → Dec 2014 | autoimmune thrombocytopenic purpura | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02280421 | Oct 2014 → Jan 2015 | — | Maruho Europe Limited | Completed | No outcome recorded |
| Phase 1 | NCT02188264 | Aug 2014 → Jan 2017 | colorectal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT02276001 | Jun → Jul 2014 | — | Kowa Research Institute, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02113293 | Mar → May 2014 | — | Novaliq GmbH | Completed | No outcome recorded |
| Phase 1 | NCT02016625 | Dec 2013 → Apr 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01968057 | Oct → Dec 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01504906 | Jan → Jun 2012 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01497483 | Dec 2011 → May 2013 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT01514968 | Dec 2011 → Feb 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01494597 | Nov → Dec 2011 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT01479881 | Oct → Dec 2011 | hepatitis C virus infection | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 1 | NCT01426334 | Sep 2011 → Jun 2012 | leukemia, myeloid, accelerated-phase | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT01437384 | Sep 2011 → Mar 2012 | autoimmune thrombocytopenic purpura | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01370343 | Jul 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01718652 | Feb → Apr 2011 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT00990795 | Apr → Oct 2010 | cardiac valvular defect | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded |
| Phase 1 | NCT00983424 | Feb 2010 → May 2013 | breast cancer | Northwestern University | Completed | No outcome recorded |
| Phase 1 | NCT01038167 | Jan → Apr 2010 | hepatitis C virus infection | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT00860496 | Jun → Aug 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00983931 | Aug → Sep 2008 | — | Mutual Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00818194 | Apr → Sep 2008 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT00783107 | Oct 2007 → Sep 2009 | chronic obstructive pulmonary disease | University of Pittsburgh | Completed | No outcome recorded |
| Phase 1 | NCT00286871 | Feb 2006 → Feb 2009 | chronic hepatitis C virus infection, disease related to solid organ transplantation | Duke University | Completed | No outcome recorded |
| Phase 1 | NCT00102583 | Oct 2004 → Mar 2011 | graft versus host disease | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1 | NCT00008450 | Aug 1997 → Oct 2011 | autosomal recessive disease, purine nucleoside phosphorylase deficiency, severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00001533 | Sep 1996 → Sep 2000 | T-cell leukemia, anemia, neutropenia, thrombocytopenia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 1 | NCT00002759 | Jun 1996 → Apr 2002 | lymphoma, neutropenia, poisoning, small intestine cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/216 trials · 3 met primary | ||||||
| Phase 1/2 | NCT05794425 | Aug 2023 → Apr 2025 | bone marrow failure syndrome | Shandong Qilu Stem Cells Engineering Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04918823 | Jul 2021 → Apr 2023 | eye adnexa disorder | Boston Sight | Completed | No outcome recorded |
| Phase 1/2 | NCT04362670 | Apr 2020 → Aug 2021 | dry eye syndrome | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02496975 | Aug 2017 | traumatic brain injury | Edward Hall,PhD | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01623167 | Jul 2012 → Jan 2018 overdue | aplastic anemia | National Heart, Lung, and Blood Institute (NHLBI) | Active not recruiting | Met primary |
| Phase 1/2 | NCT01650545 | Jul 2012 → Aug 2015 | chronic transplant rejection, disease related to solid organ transplantation, immunodeficiency disease, transplant-related bronchiolitis obliterans | University of Maryland, Baltimore | Completed | Met primary |
| Phase 1/2 | NCT01342887 | Apr 2011 → Mar 2012 | acute erythroid leukemia, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +8 | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT01193283 | Aug 2010 → Sep 2014 | aplastic anemia, neutropenia, pancytopenia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00974142 | Sep 2009 → Dec 2016 | chronic obstructive pulmonary disease | Michael Donahoe | Completed | No outcome recorded |
| Phase 1/2 | NCT00741338 | Sep 2008 → Sep 2012 | mucopolysaccharidosis type 1 | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1/2 | NCT00578370 | Nov 2007 → Apr 2008 | psoriasis | ISDIN | Completed | No outcome recorded |
| Phase 1/2 | NCT00520130 | Oct 2007 → Oct 2015 | Hodgkins lymphoma, acute leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma +1 | National Cancer Institute (NCI) | Completed | Met primary |
| Phase 1/2 | NCT00085449 | May 2006 → Jan 2007 | leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, plasma cell neoplasm | Alliance for Clinical Trials in Oncology | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00257387 | Jun 2004 → Aug 2006 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1/2 | NCT00078858 | Sep 2003 → Jan 2006 | Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, T-cell large granular lymphocyte leukemia +33 | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00002761 | Feb 1996 → Feb 2007 | leukemia | Columbia University | Withdrawn | No outcome recorded |
| Phase 292 trials · 1 met primary · 6 missed | ||||||
| Phase 2 | NCT07523009 | Jun 2026 → Dec 2028 | aplastic anemia | Peking Union Medical College Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT07124078 | May 2026 → Jan 2029 expected | chronic graft versus host disease | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 2 | NCT07558434 | Apr 2026 → Dec 2028 expected | aplastic anemia | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07138898 | Dec 2025 → Jan 2028 expected | rheumatic disorder | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 2 | NCT07029139 | Jun 2025 → Apr 2027 expected | idiopathic membranous glomerulonephritis | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07010237 | Feb 2025 → Dec 2028 expected | aplastic anemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT05946772 | Feb 2025 → Feb 2027 expected | Tako-tsubo cardiomyopathy | University Hospital Heidelberg | Recruiting | No outcome recorded |
| Phase 2 | NCT06004752 | Aug 2023 → Aug 2024 | aplastic anemia | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05733624 | Jan → Aug 2023 | dry eye syndrome | SCAI Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT05399732 | Dec 2022 → Feb 2025 | aplastic anemia | Bing Han | Completed | No outcome recorded |
| Phase 2 | NCT05459649 | Jul 2022 → Jul 2024 | autoimmune thrombocytopenia | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03602898 | Jun 2021 → Sep 2023 | Hodgkins lymphoma, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia +3 | Fred Hutchinson Cancer Center | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04781803 | Mar 2021 → Jan 2023 | cytokine release syndrome, disease related to hematopoietic stem cell transplant | Hospital Universitario Dr. Jose E. Gonzalez | Unknown | No outcome recorded |
| Phase 2 | NCT04888741 | Feb 2021 → Aug 2027 expected | Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +4 | University of Birmingham | Recruiting | No outcome recorded |
| Phase 2 | NCT04492891 | Nov 2020 → Dec 2021 | COVID-19 | Bryan Burt, MD | Completed | No outcome recorded |
| Phase 2 | NCT04488081 | Jul 2020 → Jul 2028 expected | COVID-19 | QuantumLeap Healthcare Collaborative | Active not recruiting | Missed primary |
| Phase 2 | NCT03456817 | Jul 2020 → May 2025 | graft versus host disease | AHS Cancer Control Alberta | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04304820 | May 2020 → Dec 2024 overdue | aplastic anemia | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | No outcome recorded |
| Phase 2 | NCT04107675 | Feb 2020 → Jun 2022 | bronchiolitis obliterans syndrome, chronic graft versus host disease | Zambon SpA | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03382301 | Aug 2018 → Jun 2020 | renal artery obstruction | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 2 | NCT03676335 | May 2018 → Jun 2019 | dry eye syndrome | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02998645 | May 2017 → Nov 2020 | acquired aplastic anemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02904772 | Oct 2016 → Jun 2020 | familial lipoprotein lipase deficiency | UniQure Biopharma B.V. | Withdrawn | No outcome recorded |
| Phase 2 | NCT02865356 | Sep 2016 → Apr 2017 | atopic eczema | Spherium Biomed | Completed | No outcome recorded |
| Phase 2 | NCT02917512 | Mar → Dec 2016 | dry eye syndrome | Huons Co., Ltd. | Completed | Missed primary |
| Phase 2 | NCT02617667 | Jan → Jul 2016 | dry eye syndrome | Novaliq GmbH | Completed | No outcome recorded |
| Phase 2 | NCT01901471 | Sep → Oct 2015 | acute myocardial infarction | Hospices Civils de Lyon | Withdrawn | No outcome recorded |
| Phase 2 | NCT02366585 | Mar 2015 → Sep 2016 | periodontitis | PerioC Limited | Completed | No outcome recorded |
| Phase 2 | NCT02203396 | Aug 2014 → Sep 2016 | aplastic anemia | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
| Phase 2 | NCT02173106 | Jun 2014 → Dec 2016 | idiopathic membranous glomerulonephritis, proteinuria | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT02144025 | May 2014 → Feb 2016 | graft versus host disease | Hospital Universitario Dr. Jose E. Gonzalez | Completed | No outcome recorded |
| Phase 2 | NCT02013791 | Apr 2014 → Apr 2017 | dry eye syndrome | Allergan | Terminated | No outcome recorded |
| Phase 2 | NCT02114073 | Apr → Nov 2014 | open-angle glaucoma | Mashhad University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01938625 | Dec 2013 → Apr 2015 | chronic hepatitis C virus infection | Janssen R&D Ireland | Completed | No outcome recorded |
| Phase 2 | NCT02225756 | Dec 2013 → Sep 2017 | abdominal aortic aneurysm | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 2 | NCT01990898 | Nov 2013 → Oct 2015 | interstitial cystitis | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 2 | NCT01817582 | May 2013 → Jan 2014 | dry eye syndrome | Bausch & Lomb Incorporated | Completed | Missed primary |
| Phase 2 | NCT01624805 | Jun 2012 → Jun 2029 expected | aplastic anemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT01273207 | Mar 2012 → May 2019 | graft versus host disease, transplant-related bronchiolitis obliterans | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT01596062 | Mar 2012 → Mar 2013 | — | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT01552629 | Jan 2012 → Aug 2013 | atopic eczema | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02176733 | Jul 2011 → Oct 2015 | Leber hereditary optic neuropathy | University Hospital, Angers | Unknown | Missed primary |
| Phase 2 | NCT01287078 | Jan 2011 → Aug 2018 | graft versus host disease, transplant-related bronchiolitis obliterans | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00977977 | Dec 2010 → Dec 2027 expected | autoimmune disease, membranous glomerulonephritis, nephrotic syndrome, proteinuria | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | No outcome recorded |
| Phase 2 | NCT00919776 | Aug 2010 → Dec 2012 | leprosy | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00919451 | Aug 2010 → Jun 2013 | leprosy | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00919542 | Jul 2010 → Dec 2012 | leprosy | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01109056 | Jun 2010 → May 2011 | pterygium | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT01120132 | May → Aug 2010 | conjunctivitis | Fovea Pharmaceuticals SA | Completed | No outcome recorded |
| Phase 2 | NCT01033305 | Mar 2010 → Aug 2011 | ulcerative colitis | Sigmoid Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01693393 | Mar 2010 → Oct 2014 | Sjogren syndrome | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 2 | NCT00991458 | Oct 2009 → Apr 2011 | — | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT01268995 | Sep 2009 → Dec 2010 | disease related to solid organ transplantation | Medical University of Vienna | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00944749 | Aug 2009 → Dec 2015 | aplastic anemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00824811 | Jun 2009 → ? | excessive tearing | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00840827 | Dec 2008 → Dec 2010 | myelodysplastic syndrome | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 2 | NCT01530555 | Apr 2008 → Jul 2013 | acquired aplastic anemia | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| Phase 2 | NCT01050855 | Jan 2008 → Jul 2024 | immunodeficiency disease, inherited hemoglobinopathy | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| Phase 2 | NCT00377325 | Jun 2007 → Jun 2013 | psoriasis | University of Rochester | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00895739 | Jun 2006 → ? | benign neoplasm | Federico II University | Unknown | No outcome recorded |
| Phase 2 | NCT00363779 | Jun 2006 → Nov 2010 | T-cell large granular lymphocyte leukemia | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00070291 | Jan 2006 → Mar 2009 | lymphoma | Eastern Cooperative Oncology Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00260689 | Nov 2005 → May 2016 | neutropenia, pancytopenia, thrombocytopenia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00135694 | Oct 2005 → Sep 2015 | chronic hepatitis C virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00806598 | May 2005 → Jun 2012 | aplastic anemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01231841 | Mar 2005 → Dec 2010 | aplastic anemia | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00066794 | Jul 2004 → Feb 2007 | leukemia | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00110110 | Jun 2004 → Apr 2016 | retinoblastoma | The Hospital for Sick Children | Unknown | No outcome recorded |
| Phase 2 | NCT00089050 | May 2004 → Mar 2006 | leukemia | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00948727 | Jan 2004 → Sep 2006 | graft versus host disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT00143806 | Oct 2003 → May 2007 | psoriasis | University of Medicine and Dentistry of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT00061360 | Jun 2003 → Feb 2006 | aplastic anemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Missed primary |
| Phase 2 | NCT00051311 | Jan 2003 → Sep 2014 | hematopoietic and lymphoid cell neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00031980 | Mar 2002 → May 2005 | anemia, leukemia, neutropenia, thrombocytopenia | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00976300 | Jan 2002 → May 2008 | lupus nephritis, systemic lupus erythematosus | Institute of Rheumatology, Prague | Completed | No outcome recorded |
| Phase 2 | NCT00016419 | Aug 2001 → Jul 2003 | leukemia, myelodysplastic syndrome | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00035555 | Mar 2001 → Jan 2004 | transplant rejection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00024050 | Feb 2001 → Aug 2007 | leukemia, myelodysplastic syndrome | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00009009 | Jan 2001 → Dec 2002 | HIV infectious disease, chronic renal failure syndrome | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT00005937 | Jun 2000 → Mar 2008 | myelodysplastic syndrome | Neal Young, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT00005935 | Jun 2000 → Mar 2002 | aplastic anemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00295425 | May 2000 → Oct 2006 | psoriasis | University Hospital Muenster | Unknown | No outcome recorded |
| Phase 2 | NCT00001964 | Mar 2000 → Dec 2003 | acquired aplastic anemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00001965 | Dec 1999 → Feb 2001 | hypertrophic cardiomyopathy | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00004482 | Dec 1999 → Jul 2005 | giant cell myocarditis | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00001839 | Dec 1998 → May 2000 | myelodysplastic syndrome | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 2 | NCT00001749 | Jul 1998 → Jul 2005 | Fanconi anemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00268515 | Apr 1998 → Mar 2003 | lung disorder | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Missed primary |
| Phase 2 | NCT00002688 | Feb 1995 → ? | leukemia | University Medical Center Groningen | Unknown | No outcome recorded |
| Phase 2 | NCT00000524 | Jul 1986 → Mar 1994 | myocarditis | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT00000880 | ? → May 2000 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00031070 | ? → Dec 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/39 trials · 1 met primary | ||||||
| Phase 2/3 | NCT04637633 | Aug → Oct 2020 | epiphora due to insufficient drainage | Farwaniya Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT03292809 | Oct 2017 → May 2018 | dry eye syndrome | Novaliq GmbH | Completed | No outcome recorded |
| Phase 2/3 | NCT02416388 | Jan 2015 → Jul 2025 overdue | acute myeloid leukemia | University Hospital, Angers | Recruiting | Met primary |
| Phase 2/3 | NCT00919815 | Aug 2010 → Dec 2012 | leprosy | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 2/3 | NCT00773292 | Aug 2006 → Jan 2010 | tropical spastic paraparesis | Imperial College London | Completed | No outcome recorded |
| Phase 2/3 | NCT00328653 | May 2006 → Feb 2007 | vernal conjunctivitis | Santen SAS | Completed | Mixed |
| Phase 2/3 | NCT00403728 | Sep 2004 → ? | myocardial infarction | Hospices Civils de Lyon | Unknown | No outcome recorded |
| Phase 2/3 | NCT00070187 | Nov 2003 → Jun 2005 | lymphoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2/3 | NCT00003187 | May 1995 → Feb 2005 | leukemia, lymphoma, myelodysplastic syndrome | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 375 trials · 2 met primary · 10 missed | ||||||
| Phase 3 | NCT07653581 | Jun 2026 → Dec 2028 expected | myelodysplastic syndrome | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07522996 | Jun 2026 → Dec 2028 | aplastic anemia | Peking Union Medical College Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT07548671 | Apr 2026 → Dec 2028 expected | aplastic anemia | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06658002 | Sep 2025 → Sep 2027 expected | corneal ulcer, fungal keratitis | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 3 | NCT06766357 | Apr 2025 → Feb 2026 overdue | dry eye syndrome | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06392438 | Apr 2024 → Sep 2025 | dry eye syndrome | University of Sherbrooke | Unknown | No outcome recorded |
| Phase 3 | NCT05743764 | Mar 2023 → Feb 2024 | dry eye syndrome | Huons Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04979884 | Jan → Sep 2022 | acute respiratory distress syndrome, cytokine release syndrome, pulmonary fibrosis | Alexandria University | Completed | No outcome recorded |
| Phase 3 | NCT05057468 | Oct 2021 → Nov 2026 expected | autoimmune hemolytic anemia | Assiut University | Recruiting | No outcome recorded |
| Phase 3 | NCT04877288 | Jul 2021 → Dec 2032 expected | — | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 3 | NCT04735510 | May → Sep 2021 | eye adnexa disorder | Boston Sight | Withdrawn | No outcome recorded |
| Phase 3 | NCT04743739 | Apr 2021 → Dec 2022 | idiopathic membranous glomerulonephritis | Peking Union Medical College Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT05841043 | Mar 2021 → Apr 2022 | dry eye syndrome | Jiangsu HengRui Medicine Co., Ltd. | Completed | Mixed |
| Phase 3 | NCT04523142 | Jan 2021 → Apr 2022 | dry eye syndrome | Novaliq GmbH | Completed | No outcome recorded |
| Phase 3 | NCT04523129 | Dec 2020 → Sep 2021 | dry eye syndrome | Novaliq GmbH | Completed | Mixed |
| Phase 3 | NCT04541888 | Nov 2020 → Aug 2021 | dry eye syndrome | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05245604 | Jun 2020 → Aug 2022 | dry eye syndrome | Taejoon Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04039347 | Mar 2020 → Feb 2026 | transplant-related bronchiolitis obliterans | Zambon SpA | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT04144413 | May 2019 → Jul 2023 | keratitis | Santen SAS | Completed | No outcome recorded |
| Phase 3 | NCT04384991 | May → Dec 2019 | dry eye syndrome | Huons Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03656926 | Mar 2019 → Mar 2024 | bronchiolitis obliterans syndrome, chronic transplant rejection | Zambon SpA | Completed | Missed primary |
| Phase 3 | NCT03461575 | Jan → Jul 2018 | dry eye syndrome | Huons Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02887807 | Jan 2017 → Jan 2019 | cardiac arrest | Hospices Civils de Lyon | Withdrawn | No outcome recorded |
| Phase 3 | NCT02876250 | Jan 2017 → Sep 2018 | — | Hospices Civils de Lyon | Withdrawn | No outcome recorded |
| Phase 3 | NCT02834468 | Jun 2016 → Jul 2018 | thrombocytopenia due to immune destruction | Shandong University | Unknown | No outcome recorded |
| Phase 3 | NCT02688556 | Feb → Nov 2016 | keratoconjunctivitis | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01762644 | Aug 2015 → May 2016 | type 1 diabetes mellitus | Perle Bioscience, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT04714099 | Jan → Dec 2015 | dry eye syndrome | Alexandria University | Completed | No outcome recorded |
| Phase 3 | NCT01762657 | Sep 2014 → Sep 2015 | type 1 diabetes mellitus | Perle Bioscience, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02934217 | Mar 2014 → Jun 2017 | ST-elevation myocardial infarction | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 3 | NCT02229955 | Dec 2013 → Apr 2014 | dry eye syndrome | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01751126 | Apr 2013 → Feb 2016 | vernal keratoconjunctivitis | Santen SAS | Completed | Met primary |
| Phase 3 | NCT01768312 | Aug 2012 → Jul 2013 | dry eye syndrome | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01597778 | Jun 2012 → Sep 2020 | Burkitt lymphoma, Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia +2 | Medical College of Wisconsin | Completed | Missed primary |
| Phase 3 | NCT01650662 | Jan 2012 → Oct 2014 | acute myocardial infarction | Mario Negri Institute for Pharmacological Research | Completed | Missed primary |
| Phase 3 | NCT01410448 | Nov 2011 → Dec 2015 | — | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT01502774 | Apr 2011 → Feb 2015 | ST-elevation myocardial infarction | Hospices Civils de Lyon | Completed | Missed primary |
| Phase 3 | NCT01299922 | Feb 2011 → Mar 2014 | lupus nephritis | Hospital Universitario Fundación Alcorcón | Withdrawn | No outcome recorded |
| Phase 3 | NCT01595958 | Jun 2010 → Mar 2013 | sudden cardiac arrest | Hospices Civils de Lyon | Completed | Missed primary |
| Phase 3 | NCT00938236 | Dec 2009 → Sep 2011 | bronchiolitis obliterans syndrome | APT Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00884585 | May 2009 → Oct 2010 | atopic conjunctivitis | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01023815 | Apr 2009 → Jul 2012 | — | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT02779114 | Jan 2009 → Dec 2017 | rheumatoid arthritis | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
| Phase 3 | NCT00987207 | Oct 2008 → Sep 2010 | aortic valve disorder | Hospices Civils de Lyon | Completed | Met primary |
| Phase 3 | NCT00755040 | Oct 2008 → Dec 2014 | graft versus host disease, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm +1 | Vanderbilt-Ingram Cancer Center | Completed | Missed primary |
| Phase 3 | NCT00658320 | Feb 2008 → Aug 2010 | — | Novartis | Completed | Mixed |
| Phase 3 | NCT00713193 | Nov 2007 → Sep 2017 | thrombotic thrombocytopenic purpura | Ohio State University | Completed | Missed primary |
| Phase 3 | NCT00447642 | Apr 2007 → Aug 2008 | corneal disorder, transplant rejection | Lux Biosciences, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00426023 | Feb 2007 → Oct 2008 | vernal keratoconjunctivitis | Campus-Bio-Medico University | Completed | No outcome recorded |
| Phase 3 | NCT00389870 | Dec 2006 → ? | colorectal cancer | University of Leeds | Completed | Missed primary |
| Phase 3 | NCT00375895 | Jun 2006 → Oct 2008 | chronic hepatitis C virus infection | Rennes University Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01276457 | May 2006 → Feb 2009 | disease related to solid organ transplantation | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00334672 | Mar 2006 → Nov 2010 | — | Children's Cancer and Leukaemia Group | Unknown | No outcome recorded |
| Phase 3 | NCT00300274 | Jan 2006 → Jul 2011 | transplant rejection | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01170351 | Dec 2005 → Dec 2013 | autoimmune hepatitis | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00267189 | Nov 2005 → Nov 2007 | — | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT00251004 | Oct 2005 → Aug 2009 | transplant rejection | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00154284 | Jul 2005 → Jul 2008 | disease related to solid organ transplantation | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00167947 | Jan 2005 → Jul 2007 | graft versus host disease, kidney failure | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02686619 | Nov 2004 → Jan 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00232063 | May 2004 → Nov 2005 | atopic eczema | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00232076 | May 2004 → Mar 2005 | atopic eczema | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00426101 | Jan 2004 → Dec 2011 | hemophagocytic syndrome | Karolinska University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00099736 | May 2003 → Sep 2005 | — | Novartis Pharmaceuticals | Completed | Mixed |
| Phase 3 | NCT00273871 | Jan 2002 → Sep 2006 | kidney failure, transplant rejection | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00048152 | Dec 2000 → Mar 2006 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00213590 | Apr 2000 → Nov 2006 | kidney failure | University Hospital, Rouen | Completed | No outcome recorded |
| Phase 3 | NCT00000936 | Nov 1999 → Mar 2004 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 3 | NCT00428064 | May 1998 → Jun 2004 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00003414 | Oct 1997 → May 2004 | graft versus host disease, lymphoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 3 | NCT00008203 | May 1996 → Dec 2005 | female breast carcinoma | Herbert Irving Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00002456 | May 1986 → Apr 2002 | acute graft versus host disease, leukemia, lymphoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00549289 | — | dry eye syndrome | Sirion Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00548301 | — | dry eye syndrome | Sirion Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00502073 | — | dry eye syndrome | Sirion Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 481 trials · 4 met primary | ||||||
| Phase 4 | NCT07368595 | Sep 2026 → Mar 2027 expected | dry eye syndrome | Baylor College of Medicine | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07352566 | Aug 2026 → Jun 2030 expected | atopic eczema, psoriasis | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07224529 | Jun 2026 → Feb 2027 expected | — | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 4 | NCT07553455 | Apr → Dec 2026 expected | dry eye syndrome | Canyon City Eyecare | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07025811 | Jul 2025 → Jul 2026 overdue | dry eye syndrome | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06424639 | May 2024 → May 2025 | aplastic anemia | Peking Union Medical College Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT04515329 | Dec 2023 | dry eye syndrome | Vishal Jhanji | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT06482177 | Oct 2023 → Jun 2024 | dry eye syndrome | Research Insight LLC | Completed | No outcome recorded |
| Phase 4 | NCT05867329 | Sep 2023 → May 2026 overdue | ulcerative colitis | Berinstein, Jeffrey | Recruiting | No outcome recorded |
| Phase 4 | NCT06009497 | Aug 2023 → Dec 2024 | aplastic anemia | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT06043908 | Aug 2022 → Dec 2023 | dry eye syndrome | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05696977 | Apr 2022 → Feb 2024 | nephrotic syndrome | Alexandria University | Unknown | No outcome recorded |
| Phase 4 | NCT06824844 | Dec 2021 → Mar 2024 | dry eye syndrome | Peking University Third Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04895423 | Nov 2021 → Jul 2023 | atopic eczema | National Medical Research Center for Children's Health, Russian Federation | Unknown | No outcome recorded |
| Phase 4 | NCT04835623 | Jun 2021 → Mar 2024 | Sjogren syndrome, dry eye syndrome | Center for Ophthalmic and Vision Research, LLC | Completed | No outcome recorded |
| Phase 4 | NCT04775303 | Sep 2020 → Jan 2022 | dry eye syndrome | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT04357795 | Jun 2020 → Jun 2022 | dry eye syndrome | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT04424862 | Jun 2020 → Feb 2021 | — | Beijing Friendship Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04392531 | Apr 2020 → Mar 2021 | COVID-19 | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Completed | No outcome recorded |
| Phase 4 | NCT04342988 | Apr → Dec 2020 | dry eye syndrome | Research Insight LLC | Completed | No outcome recorded |
| Phase 4 | NCT05294666 | Apr 2020 → Jun 2021 | graft versus host disease | Peking University Third Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04492878 | Feb 2020 → Jan 2021 | dry eye syndrome | Institute of Applied Ophthalmobiology - IOBA | Completed | No outcome recorded |
| Phase 4 | NCT04172961 | Feb 2020 → Dec 2022 | dry eye syndrome | Toyos Clinic | Unknown | No outcome recorded |
| Phase 4 | NCT04636918 | Nov 2019 → Aug 2022 | leukemia, myelodysplastic syndrome with excess blasts-1 | Singapore Eye Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT04127851 | Nov 2019 → Jul 2021 | dry eye syndrome | Taejoon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT04009525 | Jul 2019 → Jul 2023 | beta-thalassemia major | First Affiliated Hospital of Guangxi Medical University | Completed | No outcome recorded |
| Phase 4 | NCT03710044 | Jan 2019 → Aug 2020 | atopic eczema | LEO Pharma | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT02907554 | Dec 2017 → Apr 2022 | cardiac arrest | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 4 | NCT03237936 | Mar 2017 → Jul 2018 | keratitis | Santen SAS | Completed | No outcome recorded |
| Phase 4 | NCT02554981 | Jul 2015 → Mar 2016 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT02121847 | Apr → Sep 2014 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT02058875 | Feb 2014 → Oct 2015 | cardiovascular disorder, disease related to solid organ transplantation | University of Saskatchewan | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT01950819 | Dec 2013 → Feb 2017 | end stage renal failure | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT02004067 | Jan 2013 → Aug 2016 | Sjogren syndrome, dry eye syndrome | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 4 | NCT01699360 | Sep 2012 → Sep 2013 | — | Central South University | Unknown | No outcome recorded |
| Phase 4 | NCT02108301 | Dec 2011 → Jun 2013 | chronic hepatitis C virus infection | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 4 | NCT01817322 | Jun 2011 → Aug 2013 | chronic kidney disease | Samsung Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01002339 | Feb 2010 → Feb 2014 | type 2 diabetes mellitus | Armando Torres Ramírez | Terminated | Mixed |
| Phase 4 | NCT03150134 | Jan 2010 → Jan 2020 | acute myeloid leukemia, disease related to hematopoietic stem cell transplant | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT01266148 | Nov 2009 → Dec 2012 | — | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT00938860 | Sep 2009 → May 2013 | hepatitis C virus infection | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01706471 | Jun 2009 → Jan 2013 | — | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT00862979 | Feb 2009 → Mar 2017 | — | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT00663455 | Dec 2008 → Dec 2012 | — | University of Erlangen-Nürnberg Medical School | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01211327 | Jul → Nov 2008 | vernal keratoconjunctivitis | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT00766909 | Mar 2008 → Jun 2010 | diabetes mellitus, disease related to solid organ transplantation | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT00541814 | Oct 2007 → Feb 2010 | chronic transplant rejection | University Hospital Birmingham | Unknown | No outcome recorded |
| Phase 4 | NCT00525681 | Sep 2007 → May 2008 | — | University of Oslo School of Pharmacy | Completed | No outcome recorded |
| Phase 4 | NCT00812786 | Jul 2007 → May 2011 | — | University Hospital, Limoges | Completed | No outcome recorded |
| Phase 4 | NCT00704275 | Jun 2007 → Jul 2008 | dry eye syndrome | Chulalongkorn University | Unknown | No outcome recorded |
| Phase 4 | NCT01488396 | Feb 2007 → Jul 2009 | Stevens-Johnson syndrome | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT00456235 | Sep 2006 → Sep 2009 | — | University Hospital, Limoges | Completed | No outcome recorded |
| Phase 4 | NCT00332462 | May 2006 → Apr 2008 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00371826 | Mar 2006 → Jun 2012 | disease related to solid organ transplantation | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00337493 | Dec 2005 → Jan 2008 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00377962 | Dec 2005 → Feb 2010 | disease related to solid organ transplantation | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00264355 | Dec 2005 → Jun 2007 | acute kidney injury | University of Oslo School of Pharmacy | Completed | No outcome recorded |
| Phase 4 | NCT00118742 | Aug 2005 → Jul 2008 | — | Hoffmann-La Roche | Completed | Met primary |
| Phase 4 | NCT00139009 | Jun 2005 → Sep 2006 | — | University of Oslo School of Pharmacy | Completed | No outcome recorded |
| Phase 4 | NCT00493194 | May 2005 → Jul 2007 | chronic renal failure syndrome, disease related to solid organ transplantation, renal fibrosis | University Hospital, Antwerp | Unknown | No outcome recorded |
| Phase 4 | NCT00139035 | Apr 2005 → Jan 2006 | chronic renal failure syndrome | University of Oslo School of Pharmacy | Completed | No outcome recorded |
| Phase 4 | NCT00979706 | Mar 2005 → Nov 2014 | HIV infectious disease | Juan A. Arnaiz | Completed | No outcome recorded |
| Phase 4 | NCT01990118 | Nov 2004 → Dec 2005 | end stage renal failure | Penang Hospital, Malaysia | Completed | No outcome recorded |
| Phase 4 | NCT00087581 | Jun 2004 → Sep 2007 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00171509 | May 2004 → Oct 2005 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00171743 | Apr 2004 → Jan 2006 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00195468 | Mar 2004 → Nov 2006 | graft versus host disease, kidney failure | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00171717 | Feb 2004 → Dec 2005 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00150085 | Feb 2004 → Oct 2005 | — | Novartis | Terminated | No outcome recorded |
| Phase 4 | NCT00171496 | Oct 2003 → Mar 2006 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00148252 | Feb 2003 → Nov 2005 | — | University of Oslo School of Pharmacy | Terminated | No outcome recorded |
| Phase 4 | NCT00149994 | Dec 2002 → Dec 2007 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00488436 | May 2002 → Jun 2007 | myelodysplastic syndrome | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 4 | NCT00166816 | Mar 2002 → Jun 2003 | disease related to transplantation | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00681213 | May 2000 → Dec 2001 | — | University of Miami | Completed | No outcome recorded |
| Phase 4 | NCT00507793 | Apr 2000 → Jun 2002 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | Mixed |
| Phase 4 | NCT00518375 | Apr 2000 → May 2001 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00425724 | Jan 2000 → Feb 2007 | immunoglobulin A vasculitis | Oulu University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00209859 | Oct 1998 → Nov 2007 | rheumatoid arthritis | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00349583 | — | cataract, dry eye syndrome | Innovative Medical | Completed | No outcome recorded |
| Phase 4 | NCT00383396 | — | pterygium | Innovative Medical | Completed | No outcome recorded |
| Phase not applicable29 trials · 1 met primary · 1 missed | ||||||
| — | NCT07406932 | May 2026 → Jul 2027 expected | antisynthetase syndrome, interstitial lung disease | China-Japan Friendship Hospital | Recruiting | No outcome recorded |
| — | NCT06898853 | Jun 2025 → Dec 2026 expected | dry eye syndrome | The University of New South Wales | Recruiting | No outcome recorded |
| — | NCT06981104 | Nov 2024 → Feb 2025 | asthenopia, dry eye syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| — | NCT07171710 | Mar 2024 → Mar 2026 overdue | dry eye syndrome | Tianjin Eye Hospital | Enrolling by invitation | No outcome recorded |
| — | NCT06147375 | Dec 2023 → Dec 2026 expected | — | Wei Gao | Not yet recruiting | No outcome recorded |
| — | NCT05957211 | May 2023 → Feb 2024 | dry eye syndrome | University of Waterloo | Completed | No outcome recorded |
| — | NCT05782933 | Aug 2022 → Dec 2023 | idiopathic membranous glomerulonephritis | Beijing Friendship Hospital | Unknown | No outcome recorded |
| — | NCT05131152 | Dec 2021 → Jul 2023 | dry eye syndrome | Zhongshan Ophthalmic Center, Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT05771012 | Jan 2021 → Oct 2022 | stenosis of lacrimal punctum | Farwaniya Hospital | Completed | No outcome recorded |
| — | NCT04705584 | Jan → Oct 2021 | vernal keratoconjunctivitis | Assiut University | Unknown | No outcome recorded |
| — | NCT05691764 | Sep 2020 → Dec 2021 | — | Indonesia University | Completed | Met primary |
| — | NCT04597762 | Aug 2020 → Mar 2021 | dry eye syndrome | Hospital Hietzing | Completed | No outcome recorded |
| — | NCT06936462 | Jan 2020 → Jan 2024 | dry eye syndrome | Hallym University Kangnam Sacred Heart Hospital | Completed | No outcome recorded |
| — | NCT04906304 | Jan → Jul 2020 | cytomegalovirus infection | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| — | NCT03403023 | Jan → May 2018 | dry eye syndrome | Meir Medical Center | Unknown | No outcome recorded |
| — | NCT02199964 | Mar 2014 → Dec 2015 | dry eye syndrome | Baylor College of Medicine | Terminated | No outcome recorded Stop: Business |
| — | NCT01936519 | Dec 2013 → Jul 2019 | immunodeficiency disease, kidney failure | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| — | NCT01547143 | Mar 2012 → May 2016 | secondary hemophagocytic lymphohistiocytosis | Asan Medical Center | Terminated | No outcome recorded |
| — | NCT01149759 | Jun 2010 → Dec 2014 | atopic eczema | Rockefeller University | Completed | No outcome recorded |
| — | NCT00987467 | Aug 2007 → Sep 2009 | atopic keratoconjunctivitis | Johns Hopkins University | Completed | No outcome recorded |
| — | NCT00335114 | Nov 2005 → Apr 2006 | dry eye syndrome | University of Alabama at Birmingham | Completed | No outcome recorded |
| — | NCT00148746 | May 2004 → Sep 2006 | atopic eczema | Technical University Dresden | Completed | Missed primary |
| — | NCT02226068 | Jun 2002 → Aug 2003 | atopic eczema | University of Aarhus | Completed | No outcome recorded |
| — | NCT00027443 | Aug 2001 → Jul 2007 | myocarditis | Mayo Clinic | Completed | No outcome recorded |
| — | NCT00014235 | Dec 2000 → Feb 2005 | Burkitt lymphoma, CD4+/CD56+ hematodermic neoplasm, Hodgkins lymphoma, MALT lymphoma +37 | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| — | NCT00007787 | Apr 2000 → Mar 2004 | chronic transplant rejection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00006054 | Mar 2000 → Dec 2002 | Bruton-type agammaglobulinemia, Chediak-Higashi syndrome, Wiskott-Aldrich syndrome, X-linked lymphoproliferative syndrome +6 | Fairview University Medical Center | Terminated | No outcome recorded |
| — | NCT00905073 | Feb 1990 → Jun 1994 | type 1 diabetes mellitus | Georgetown University | Completed | No outcome recorded |
| — | NCT00433277 | — | retinitis pigmentosa | Semmelweis University | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT00633373 | — | transplant-related bronchiolitis obliterans | APT Pharmaceuticals, Inc. | No longer available | No outcome recorded |
| Comparator or background therapy481 trials | ||||||
| Phase 0 | NCT06949267 Background | Jun 2025 → Sep 2026 overdue | acute graft versus host disease | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT04988256 Comparator | Sep 2021 → Apr 2026 overdue | drug rash with eosinophilia and systemic symptoms | University of Southern California | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT02653196 Background | Sep 2015 → Aug 2017 | neuroepithelial neoplasm | Montefiore Medical Center | Terminated | No outcome recorded |
| Phase 0 | NCT02181478 Background | Jul 2015 → Dec 2019 | B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, acute myeloid leukemia, chronic myeloid leukemia +2 | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT01380535 Background | Nov 2011 → Mar 2015 | chronic graft versus host disease | Mallinckrodt | Completed | Missed primary |
| Show all 481 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 36
| Date | Issuer | Release |
|---|---|---|
| 2026-06-30 | Novaliq GmbH | Regulatory Hengrui’s Heng Yi ® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease novaliq.com ↗
Heng Yi ® is the first and only water-free 0.1% cyclosporine ophthalmic solution and the second dry eye disease drug product approved in China based on the EyeSol ® platform technology, following the approval of Heng Qin ® (perfluorohexyloctane ophthalmic solution) in 2025. |
| 2025-12-01 | Impax Laboratories, LLC | Regulatory Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% amneal.com ↗
Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. |
| 2025-08-27 | Théa Open Innovation, France | Regulatory Théa & Novaliq Launch Vevizye® thea.com ↗
Vevizye® is based on Novaliq’s proprietary EyeSol® technology and the only water-free ciclosporin 0.1% eye drops solution and is approved in the European Union for the treatment of moderate to severe dry eye disease (keratoconjunctivitis sicca) in adult patients which has not improved despite treatment with tear substitutes. |
| 2024-07-29 | Novaliq GmbH | Regulatory Novaliq Receives Positive CHMP Opinion FOR Vevizye ® in Dry EYE Disease novaliq.com ↗
The positive opinion is based on the CHMP review of the comprehensive data package from more than 1.500 patients with moderate to severe DED. |
| 2024-07-05 | Saptalis Pharmaceuticals LLC | Regulatory Saptalis Pharmaceuticals Receives FDA Approval for Cyclosporine Ophthalmic Emulsion, 0.05% saptalis.com ↗
Saptalis Pharmaceuticals, LLC is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Cyclosporine Ophthalmic Emulsion, 0.05%. |
| 2024-06-05 | Harrow Inc | Results Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study harrow.com ↗ |
| 2023-10-12 | Sun Pharmaceutical Industries, Inc. | Results CEQUA® (cyclosporine ophthalmic solution) 0.09% Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients Switched From Restasis® (cyclosporine ophthalmic emulsion) 0.05% sunpharma.com ↗
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced the presentation of Phase 4 data showing that CEQUA® (cyclosporine ophthalmic solution) 0.09% induces sustained improvement in the signs and symptoms of dry eye disease (DED). |
| 2023-08-24 | Novaliq GmbH | Regulatory European Medicines Agency Accepts Novaliq’s Marketing Authorization Application for CyclASol ® (Ciclosporin eye drops, solution 1 mg/mL) for the Treatment of Dry Eye Disease novaliq.com ↗
Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for CyclASol (ciclosporin ophthalmic solution) for regulatory review. |
| 2023-06-08 | Novaliq GmbH | Regulatory Novaliq Announces FDA Approval of VEVYE ™ (Cyclosporine Ophthalmic Solution) 0.1%, for the Treatment of the Signs and Symptoms of Dry Eye Disease novaliq.com ↗ |
| 2023-04-12 | Novaliq GmbH | Results Novaliq announces publication of second pivotal phase 3 trial data on CyclASol ® 0.1% (Cyclosporine Ophthalmic Solution) in JAMA Ophthalmology novaliq.com ↗
In ESSENCE-2, 71.6% of CyclASol ® treated patients showed such a response after 4 weeks of treatment, significantly more than in the vehicle group. |
| 2023-03-21 | Novaliq GmbH | Regulatory Marketing Authorization Application for Dry Eye Disease Drug SHR8028 (Cyclosporine Ophthalmic Solution) developed by Jiangsu Hengrui Pharmaceutical has been accepted in the People’s Republic of China novaliq.com ↗
The marketing authorization application for SHR8028 (cyclosporine ophthalmic solution) eye drops for the treatment of the signs and symptoms of dry eye disease was accepted by NMPA. |
| 2022-10-24 | Novaliq GmbH | Regulatory Novaliq announces FDA acceptance of the new drug application for CyclASol ® for the treatment of dry eye disease novaliq.com ↗
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol ® water-free technology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for CyclASol ® (cyclosporine ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment for the signs and symptoms of dry eye disease (DED). |
| 2022-08-09 | Novaliq GmbH | Regulatory Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol ® novaliq.com ↗
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol ® water-free technology, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for CyclASol ® (cyclosporine ophthalmic solution), a proposed novel treatment for the signs and symptoms of dry eye disease (DED). |
| 2022-05-10 | Santen Gmbh | Regulatory Santen Received the Approval of Verkazia (Ciclosporin Eye Drops (III)), Providing New Solutions for Severe Vernal Keratoconjunctivitis in China santen.com ↗
The approval of Verkazia® will provide more effective and safe choices for ophthalmologists in terms of VKC management plans and thus benefit more VKC patients. |
| 2022-04-27 | Novaliq GmbH | Results Novaliq Presents Data from Second Phase 3 Trial of Investigational Treatment CyclASol ® at ASCRS Annual Meeting novaliq.com ↗
The ESSENCE-2 data confirms that CyclASol ® has consistent and superior therapeutic effects on the ocular surface in patients with dry eye disease. |
| 2022-02-03 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Regulatory Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease viatris.com ↗
The approval of generic Restasis reinforces our ongoing commitment to deliver innovative solutions and increase access to more affordable treatment options for patients. |
| 2021-12-21 | Novaliq GmbH | Results Novaliq Announces Positive Topline Results for Second Phase 3 Trial (Essence-2) of CyclASol® in Dry Eye Disease novaliq.com ↗
CyclASol ® demonstrated superior effects over its vehicle on the primary sign endpoint, improvement of total corneal fluorescein staining (tCFS) at day 29 (pvalue = 0.0278). |
| 2021-10-28 | Ocular Therapeutix, Inc. | Results Ocular Therapeutix™ to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting ocutx.com ↗
The poster also includes the top-line results from the Phase 2 clinical trial, including the data for the primary endpoint of increased tear production at 12 weeks as measured by the Schirmer’s Test |
| 2021-10-22 | Ocular Therapeutix, Inc. | Results Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint ocutx.com ↗
Ocular Therapeutix, Inc. (Nasdaq:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline results from its Phase 2 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED). |
| 2021-06-24 | Santen Gmbh | Regulatory Santen Receives U.S. FDA Approval for Verkazia (Cyclosporine Ophthalmic Emulsion, 0.1%) for the Treatment of Vernal Keratoconjunctivitis in Children and Adults santen.com ↗
Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Verkazia (Cyclosporine ophthalmic emulsion, 0.1%) for the treatment of vernal keratoconjunctivitis (VKC) in children and adults. |
| 2021-05-17 | Harrow Inc | Results Leading Peer-Reviewed Ophthalmic Journal Publishes Study on ImprimisRx’s Proprietary Klarity-C® Drops harrow.com ↗ |
| 2020-12-01 | Santen Gmbh | Regulatory Ciclosporin Topical Ophthalmic Emulsion, 0.1% in the Treatment of Severe Vernal Keratoconjunctivitis in Patients Ages 4-18, has been added to China's third batch of Overseas New Drugs Urgently Needed in Clinical Settings, compiled by the NMPA santen.com ↗ |
| 2020-10-26 | Santen Gmbh | Regulatory Santen Announces U.S. FDA Filling Acceptance of New Drug Application(NDA) for Cyclosporine Topical Ophthalmic Emulsion, 0.1% in the Treatment of Severe Vernal Keratoconjunctivitis in Patients Ages 4-18 santen.com ↗ |
| 2020-10-08 | Ocular Therapeutix, Inc. | Results Ocular Therapeutix™ Announces Topline Phase 1 Clinical Trial Results of OTX-CSI ocutx.com ↗
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline Phase 1 clinical trial results of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED). |
| 2020-06-18 | Harrow Inc | Regulatory ImprimisRx’s Patented Klarity-C® 0.1% Cyclosporine Preservative-Free Formulation May Now Be Prescribed By Florida’s 2,000 Optometrists harrow.com ↗
ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc. ( NASDAQ: HROW ), today announced its Klarity-C preservative-free formulation (0.1% cyclosporine emulsion) may now be prescribed by Florida’s nearly 2,000 optometrists¹ as a result of the Florida Board of Optometry’s recent additions to its Formulary of Topical Ocular Pharmaceutical Agents. |
| 2018-10-17 | Novaliq GmbH | Results Novaliq announces positive topline results for its CyclASol® phase 2b/3 ESSENCE trial in patients with Dry Eye Disease novaliq.com ↗
The ESSENCE trial met its primary endpoint at 4 weeks and demonstrated superiority of CyclASol® over vehicle in change from baseline on corneal fluorescein staining |
| 2018-08-16 | Sun Pharmaceutical Industries, Inc. | Regulatory Sun Pharma Announces USFDA Approval of CEQUA to Treat Dry Eye Disease sunpharma.com ↗ |
| 2018-05-02 | RegeneRx Biopharmaceuticals, Inc. | Results ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndrome in a Mouse Model at ARVO regenerx.com ↗
Such improvements with RGN-259 treatment were comparable to or better than that seen with approved prescription treatments such as cyclosporine A (Restasis®), lifitegrast (Xiidra®), and diquafosol (Diquas®), which are marketed in the USA or Japan. |
| 2017-12-27 | Sun Pharmaceutical Industries, Inc. | Regulatory Sun Pharma Announces US FDA Acceptance of NDA for OTX-101 sunpharma.com ↗
Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) announces that the US FDA has accepted a New Drug Application (NDA), filed by its wholly owned subsidiary, for OTX-101 (cyclosporine A, ophthalmic solution) 0.09%, a novel nanomicellar formulation of cyclosporine A 0.09% in a clear, preservative-free aqueous solution. |
| 2017-01-04 | Sun Pharmaceutical Industries, Inc. | Results Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera™ for Treatment of Dry Eye sunpharma.com ↗
Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies), announced successful Phase 3 confirmatory clinical trial results for Seciera ™ (cyclosporine A, 0.09% ophthalmic solution), for the treatment of dry eye disease. |
| 2015-05-06 | Bristol-Myers Squibb | Results Long-Term, 7-Year Study of Nulojix® (belatacept) Regimen Demonstrates Statistically Significant Relative Risk Reduction of Death or Graft Loss over Cyclosporine Regimen in Kidney Transplant bms.com ↗
7-year BENEFIT results demonstrated statistically significant and sustained difference in renal function of Nulojix- versus cyclosporine-treated patients |
| 2013-10-01 | Bristol-Myers Squibb | Results Bristol-Myers Squibb to Present Range of New Hepatitis C Data at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting bms.com ↗
Daclatasvir Pharmacokinetics in Healthy Subjects: No Clinically-Significant Drug-Drug Interactions with Cyclosporine or Tacrolimus |
| 2013-04-11 | Sigmoid Pharma | Results Sigmoid Pharma Announces CyCol Data Presentation at the British and Irish Gastroenterology Spring Meeting sigmoidpharma.com ↗
Results in this short four week treatment period that used a once-daily, low dose regimen provided encouraging proof of principle that met the safety endpoint of no difference between treatment and placebo arms. |
| 2009-06-05 | InnoPharmax Inc. | Regulatory InnoPharmax announced the ANDA approvals of Immurin® 100 mg and Gadoscan® I.V. Injection innopharmax.com ↗
InnoPharmax, Inc. announced that the Department of Health (DOH) has granted approvals for the Company's Abbreviated New Drug Applications (ANDA) for Immurin® Soft Gelatin Capsule 100 mg (cyclosporine) and Gadoscan® I.V. Injection (gadodiamide). |
| 2009-05-28 | Bristol-Myers Squibb | Results First Phase III Data on Innovative Compound for Solid Organ Transplantation To be Featured at American Transplant Congress bms.com ↗
Belatacept Demonstrates Superior Composite Patient/Graft Survival in Diabetic Kidney Transplant Recipients vs. CsA: Results from the BENEFIT and BENEFIT-EXT Studies |
| 2003-12-29 | BioMarin Pharmaceutical | Results PNAS Study from BioMarin Highlights Possible New Approach for Improving the Efficacy of Enzyme and Protein Replacement Therapies biomarin.com ↗
The immunosuppressive regimen required to induce tolerance was comprised of high doses of one common immunosuppressive drug, cyclosporin A, combined with azathioprine, for several weeks during initial exposure to the enzyme |
All press releases naming this drug 60 releases
Evidence & citations 69 cited values
Every value below carries the sentence it was read from. 888 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cyclosporine | “A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT®, a CREMOPHOR® EL-free Lipid Emulsion, and SANDIMMUNE®...” NCT01692834 ↗615“Aplastic anemia can be treated effectively with allogeneic bone marrow transplantation and immunosuppressive therapy with horse anti-thymocyte globulin (h-ATG) and cyclosporine...” NCT03413306 ↗ “To compare the safety and efficacy of cyclosporine (CsA) + mycophenolate mofetil (MMF) + corticosteroids © to CsA + Rapamune + Cs with CsA elimination in the Rapamune arm with...” NCT01601821 ↗ “Healthy adult subjects will receive an IV dose of SyB V-1901 alone, simultaneous administration of SyB V-1901 with cyclosporine, and coadministration of cyclosporine at 2 hours...” NCT04542252 ↗ “Oral calcineurin inhibitors (tacrolimus 0.075 mg/kg/day in two divided doses, or cyclosporine 2-5 mg/kg/day in two divided doses) administered in combination with standard...” NCT07406932 ↗ “The goal of this clinical trial is to compare the administration of 2 drugs, cyclosporine 0.05% (Restasis) and Lifitgrast (Xiidra) before PRK, in reducing the ocular surface...” NCT06624384 ↗ “Cyclosporine micro-emulsion will be initiated when renal function is established or no later than day 10 in a dose of 3mg/kg twice daily with adjustment to achieve a C2 target...” NCT00706680 ↗ “Topical Cyclosporine 0.05% (Restasis®) is an anti-inflammatory drug which is the most recommended treatment option for patients with moderate-severe DES who failed conservative...” NCT03403023 ↗ “When a donor organ becomes available for transplant, the patient will receive three anti-rejection drugs-cyclosporine, mycophenolate mofetil and prednisone-to prevent organ rejection.” NCT00009009 ↗ “This study will compare kidney function in kidney transplant patients following treatment with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine).” NCT00048152 ↗ “This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.” NCT05733624 ↗ |
| Known as | aurosporine (cyclosporine 2%) | “aurosporine (cyclosporine 2%)” NCT02206789 ↗ |
| Known as | CEQUA | “CEQUA (cyclosporine 0.09% ophthalmic solution) improves symptoms of dry eye disease in a population of patients with Sjogren's Syndrome diagnosis.” NCT04835623 ↗ |
| Known as | CequaTM | “CequaTM (Cyclosporine 0.09%) ophthalmic solution” NCT04357795 ↗ |
| Known as | CicloMulsion (ready-to-use lipid emulsion of Cyclosporine A) | “CicloMulsion® (ready-to-use lipid emulsion of Cyclosporine A)” NCT01692834 ↗ |
| Known as | ciclosporin | “Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive...” NCT02885610 ↗43“A Phase II, Randomized, Double-blind, Placebo-controlled Study of a Controlled Release Minicapsule Formulation of Ciclosporin (CyCol™) in the Treatment of Mild to Moderate...” NCT01033305 ↗ “prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial” PMID 26645190 ↗ Nov 2015 “Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion” NCT01825044 ↗ “Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)” NCT00919815 ↗ “3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)” NCT04144413 ↗ “Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months” NCT01530555 ↗ “Effect of Ciclosporin Eyedrops on Sjögren Syndrome” NCT04597762 ↗ “IKERVIS® (1mg/mL ciclosporin) eye drops” NCT04492878 ↗ “Ciclosporin (e.g. Immunosporin®)” NCT02779114 ↗ |
| Known as | ciclosporin A | “The purpose of this work is to compare the two modalities currently accepted for the treatment of the disease, but in a prophylactic way; topical ciclosporin A against topical...” NCT06348602 ↗9“MATERIALS AND METHODS: Open label, proof of concept, pilot study of 48 weeks therapy with the calcineurin antagonist, ciclosporin A (CsA), in seven patients with 'early' (<two...” PMID 22720101 ↗ Jun 2012 “guideline recommended ciclosporin A (CsA) + anti-thymocyte immunoglobulin (ATG) + thrombopoietin receptor agonists (TPO-RA) as the first-line therapy.” NCT05996393 ↗ “Ciclosporin A (CsA) plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal” NCT01002339 ↗ “ciclosporin A （CsA）+methotrexate (MTX) +mycophenolate Mofetil(MMF)” NCT04203108 ↗ “using once-daily ciclosporin A (CsA) 0.1% cationic emulsion (CE).” PMID 42283972 ↗ Jun 2026 |
| Known as | Ciclosporin, CsA | “Ciclosporin, CsA” NCT02617667 ↗ |
| Known as | Ciclosporine (CSA) | “Ciclosporine (CSA)” NCT04523129 ↗ |
| Known as | Ciclosporine A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00456235 ↗ |
| Known as | CIS | “The nebulizer generates a mist of cyclosporine inhalation solution (CIS), which is then breathed in through a mouthpiece.” NCT01287078 ↗3“Cyclosporine USP Inhalation Solution (CIS) 300mg/4.8 mL delivered via a disposable nebulizer.” NCT00633373 ↗ “Cyclosporine Inhalation Solution (CIS)” NCT00938236 ↗ “Cyclosporine Inhalation Solution (CIS)” NCT00755781 ↗ |
| Known as | CPS | “A PHASE I/II STUDY OF RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH METHOTREXATE (MTX) AND CYCLOSPORINE (CPS)” NCT00002790 ↗ |
| Known as | CSA | “The aim of this study was to compare the long-term safety and efficacy of immunosuppressive regimens consisting of cyclosporine (CsA) plus mycophenolate mofetil (MMF) or...” PMID 19744223 ↗ Sep 2009112“MATERIALS AND METHODS: Open label, proof of concept, pilot study of 48 weeks therapy with the calcineurin antagonist, ciclosporin A (CsA), in seven patients with 'early' (<two...” PMID 22720101 ↗ Jun 2012 “Clinical trials have shown that approximately 75-80% of patients who are treated with immunosuppressive drugs, especially the combination of antithymocyte globulin (ATG) and...” NCT00005935 ↗ “Aplastic anemia can be treated effectively with allogeneic bone marrow transplantation and immunosuppressive therapy with horse anti-thymocyte globulin (h-ATG) and cyclosporine...” NCT03413306 ↗ “We conducted a single-arm, phase 2 clinical trial that investigated the addition of tocilizumab, an interleukin-6 receptor blocker, to cyclosporine-A (CSA) and mycophenolate...” PMID 40423982 ↗ May 2025 “Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1%...” NCT00328653 ↗ “To compare the safety and efficacy of cyclosporine (CsA) + mycophenolate mofetil (MMF) + corticosteroids © to CsA + Rapamune + Cs with CsA elimination in the Rapamune arm with...” NCT01601821 ↗ “Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either...” NCT06658002 ↗ “different immunosuppressive regimens (cyclosporine A [CsA]/MMF, Tacr/MMF, Tacr/MMF with conversion to Tacr/Everolimus [ERL]) or by cytokine promoter gene polymorphisms may...” NCT00160966 ↗ “Patients who were newly diagnosed with non-transfusion-dependent non-severe AA (NTD-NSAA) were randomly assigned to receive either cyclosporine (CsA) combined with luspatercept...” PMID 42057135 ↗ Apr 2026 “A total of 50 participants were randomly assigned to either the CsA group (n = 25, cyclosporine A twice a day and hyaluronic acid twice daily) or the control group (n = 25,...” NCT06936462 ↗ |
| Known as | CsA (Cyclosporin) | “CsA (Cyclosporin)” NCT00001880 ↗ |
| Known as | CsA-CE | “PURPOSE: This study evaluates the efficacy and tolerability of cyclosporine A cationic emulsion (CsA-CE) in patients ≥4 years of age with moderate-to-severe vernal...” PMID 37872059 ↗ Oct 2023 |
| Known as | CSP | “This is a prospective, randomized, placebo-controlled study about Cyclosporine A (CSP) and traumatic brain injury (TBI).” NCT02496975 ↗2“cyclosporine (CSP) and mycophenolate mofetil (MMF)” NCT01251575 ↗ “cyclosporine (CSP) at initial dose of 6.25 mg/kg” NCT00325741 ↗ |
| Known as | CyA | “This study aims to investigate the efficacy and safety of low-dose cyclosporine A (CyA) in patients with primary Sjögren's syndrome (pSS) and articular involvement.” PMID 27470087 ↗ Jul 20162“The aim of our study is to compare cyclosporine A (CyA) and methylprednisolone pulses (MP) in the treatment of severe HSN.” PMID 21626222 ↗ May 2011 “Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day” NCT00976300 ↗ |
| Known as | CyclASol | “PURPOSE: To compare the efficacy, safety, and tolerability of waterfree cyclosporine formulation (CyclASol) at 2 concentrations (0.1% and 0.05% of cyclosporine [CsA]) to...” PMID 30703441 ↗ Jan 20191“OBJECTIVE: To assess efficacy, safety, and tolerability of a water-free cyclosporine ophthalmic solution, 0.1% (CyclASol [Novaliq GmbH]), applied twice daily in DED compared...” PMID 37022717 ↗ May 2023 |
| Known as | cyclo | “Although high doses of cyclosporin (cyclo) inhibits the development of type 1 diabetes mellitus” NCT00905073 ↗ |
| Known as | Cyclosporin | “cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days)” NCT02834468 ↗44“MTX+SSZ+Plaquenil; can be changed to MTX+cyclosporin within protocol” NCT00764725 ↗ “Cyclosporin will begin on day -2 (IV or oral) for at least 180 days.” NCT01015742 ↗ “Cyclosporin is administered at a dose of 3-5mg/kg per day.” NCT06254560 ↗ “Tacrolimus, Cyclosporin, NeoOral, Prograf” NCT01455649 ↗ “Cyclosporin for inhalation twice daily” NCT01334892 ↗ “Restasis (topical cyclosporin)” NCT00348335 ↗ “topical cyclosporin eyedrops” NCT04597762 ↗ “0.05% cyclosporin eye drop” NCT00705510 ↗ “Drug: Cyclosporin (CSA)” NCT07375654 ↗ |
| Known as | Cyclosporin 0.05% emulsion (Restasis) | “Cyclosporin 0.05% emulsion (Restasis)” NCT02199964 ↗ |
| Known as | cyclosporin A | “This study compares the long-term efficacy and safety of interferon (IFN) α2a and cyclosporine (cyclosporin A, CsA) following suppression of acute attack by high-dose oral...” NCT03209219 ↗9“This study aims to explore the clinical and immunological efficacy of low-dose Interleukin-2 (IL-2) and cyclosporin a (CSA) on idiopathic inflammatory myopathy (IIM)” NCT04237987 ↗ “Experimental studies have shown that cyclosporin A (CsA) administered prior to reperfusion binds to cyclophilin D and blocks the opening of mPTP after reperfusion.” NCT02876250 ↗ “The Effects of Cyclosporin A Emulsion, (Restasis), on the Ocular Surface in Response to Low Humidity Environment in Patients With Dry Eye” NCT02199964 ↗ “Cyclosporin A is an immunomodulator that specifically inhibits T lymphocytes by blocking the expression of the interleukin-2 receptor.” NCT00987467 ↗ “These reperfusion's injuries can be reduced by injection of cyclosporin A (CsA) at the time of reperfusion.” NCT01901471 ↗ “cyclosporin A 0.05% cyclosporine A eye drops were administered three times daily to both eyes.” NCT07171710 ↗ “sulfasalazine plus hydroxychloroquine could be replaced by cyclosporin A” NCT00764725 ↗ “Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv” NCT01087398 ↗ “Cyclosporin A (Sandimmun Neoral® or similar):” NCT02936505 ↗ |
| Known as | Cyclosporin: NEORAL | “Cyclosporin: NEORAL” NCT00922129 ↗ |
| Known as | cyclosporine (Neoral, Sandimmune and other trade names) | “cyclosporine (Neoral, Sandimmune and other trade names)” NCT00132691 ↗ |
| Known as | Cyclosporine A | “A Non-randomized, Phase II Study of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A (ATG/CsA) in Subjects With Moderate or More Severe Aplastic...” NCT02404025 ↗142“The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate,...” NCT03320642 ↗ “We conducted a single-arm, phase 2 clinical trial that investigated the addition of tocilizumab, an interleukin-6 receptor blocker, to cyclosporine-A (CSA) and mycophenolate...” PMID 40423982 ↗ May 2025 “Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1%...” NCT00328653 ↗ “This is a single-center pilot study to investigate the efficacy and safety of aerosolized liposomal cyclosporine A in the treatment of chronic rejection in lung transplant...” NCT01650545 ↗ “different immunosuppressive regimens (cyclosporine A [CsA]/MMF, Tacr/MMF, Tacr/MMF with conversion to Tacr/Everolimus [ERL]) or by cytokine promoter gene polymorphisms may...” NCT00160966 ↗ “Purpose: To compare the efficacy and ocular tolerability of a 0.08% nanoemulsion cyclosporine A (CsA) (TJO-087) once daily versus a conventional 0.05% emulsion CsA twice daily...” PMID 36450107 ↗ Nov 2022 “The purpose of this work was to evaluate the effect of loteprednol etabonate (LE) before the initiation of topical cyclosporine A (tCsA) therapy in patients with...” PMID 25083776 ↗ Sep 2014 “The most accepted pharmacological modality is the topical application of cyclosporine A; on the other hand, tacrolimus has shown greater immunosuppressive power when used in...” NCT06348602 ↗ “Cyclosporine A is a calcineurin inhibitor, which has an effect on reducing T-cell proliferation and activation, can reverse pancytopenia and alleviate transfusion requirements in NSAA.” NCT05660785 ↗ “OBJECTIVE: To assess patients' experiences with topical cyclosporine A (tCSA) 0.05% ophthalmic emulsion (Restasis) to treat keratoconjunctivitis sicca (KCS) in a real-world setting.” PMID 16004673 ↗ Jul 2005 |
| Known as | Cyclosporine Capsule | “Drug: Cyclosporine Capsule” NCT05696977 ↗ |
| Known as | Cyclosporine Eye Drops (Restasis) | “Cyclosporine Eye Drops (Restasis)” NCT02461719 ↗ |
| Known as | Cyclosporine Eye Drops(CYPORIN N) | “Cyclosporine Eye Drops(CYPORIN N)” NCT02461719 ↗ |
| Known as | cyclosporine microemulsion | “Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as...” NCT00149890 ↗ |
| Known as | CycloSPORINE Ophthalmic Suspension | “Drug: CycloSPORINE Ophthalmic Suspension” NCT04705584 ↗ |
| Known as | Cyclosporine(CsA) | “Cyclosporine(CsA)” NCT05571332 ↗ |
| Known as | Cyclosporine/Neoral/Sandimmune/Gengraf | “Cyclosporine/Neoral®/Sandimmune®/Gengraf®” NCT00905515 ↗ |
| Known as | Cyclosporine: Cipol | “Cyclosporine: Cipol” NCT01547143 ↗ |
| Known as | Cyclosporins | “Drug: Cyclosporins” NCT00282412 ↗ |
| Known as | CyCol | “relative colonic mucosal concentrations of cyclosporine capsules (CyCol®) compared to intravenous cyclosporine in healthy male volunteers.” NCT02130414 ↗ |
| Known as | CyIS | “Aerosol Cyclosporine (CyIS)” NCT00783107 ↗ |
| Known as | Cylosporine A | “It is suspected that Cylosporine A (Sandimmun, TM) is less diabetogenic than Tacrolimus (Prograf, TM).” NCT01268995 ↗ |
| Known as | Cyporin N Eye Drops | “0.05% cyclosporine A (Cyporin N Eye Drops, Taejoon Pharm, Republic of Korea) and 0.15% hyaluronic acid (New Hyaluni Eye Drops, Taejoon Pharm) were used in this study.” NCT06936462 ↗ |
| Known as | CYSP | “Determine the maximum tolerated dose of irinotecan (CPT-11) when infused weekly with cyclosporine (CYSP) in patients with solid tumors or lymphoma refractory to standard therapy.” NCT00002759 ↗1“addition of cyclosporine (CYSP) to mitoxantrone (DHAD) and etoposide (VP-16)” NCT00002688 ↗ |
| Known as | Formulation 01B | “Ciclosporin 0.5% (Formulation 01B)” NCT00578370 ↗ |
| Known as | Formulation 02B | “Ciclosporin 1.5% (Formulation 02B)” NCT00578370 ↗ |
| Known as | Gengraf | “Gengraf a microemulsion formulation of CsA though granted an AB-rated equivalent to Neoral, because of concerns over the use of generic drugs in transplantation, we undertook...” NCT01990118 ↗1“Cyclosporine (Gengraf )” NCT00944749 ↗ |
| Known as | HU007 | “Purpose: To compare the efficacy and safety of HU00701 (0.01% cyclosporin A + 3% trehalose), HU007 (0.02% cyclosporin A + 3% trehalose) (all w/v), and placebo” PMID 33449860 ↗ Jan 2021 |
| Known as | HU00701 | “Purpose: To compare the efficacy and safety of HU00701 (0.01% cyclosporin A + 3% trehalose), HU007 (0.02% cyclosporin A + 3% trehalose) (all w/v), and placebo” PMID 33449860 ↗ Jan 2021 |
| Known as | Ikervis | “The active intervention arm has CsA 0.1% - Ikervis (CSL Seqirus, Parkville, Victoria) and mineral oils lubricating eye drops - Cationorm (CSL Seqirus, Parkville, Victoria)” NCT06898853 ↗2“IKERVIS® (1mg/mL ciclosporin) eye drops” NCT04492878 ↗ “Cyclosporine 0.1% (Ikervis®) eye drop” NCT04775303 ↗ |
| Known as | Immunosporin | “Ciclosporin (e.g. Immunosporin®)” NCT02779114 ↗ |
| Known as | L-CsA | “This is a randomized single-center pilot study to investigate the efficacy and safety of aerosolized liposomal cyclosporine A (L-CsA) in the treatment of chronic rejection in...” NCT01650545 ↗1“L-CsA” NCT04039347 ↗ |
| Known as | Liposomal Cyclosporine A | “Liposomal Cyclosporine A (L-CsA) 10 mg twice daily for 48 weeks, plus Standard of Care Therapy” NCT03656926 ↗1“Liposomal Cyclosporine A 5 mg” NCT04039347 ↗ |
| Known as | Neoral | “Group C received cyclosporine A (CsA) (Neoral, Novartis, Basel, Switzerland) and sirolimus with target CsA trough levels of 225 and 175 ng/mL at 1 month and 1 year.” PMID 14742989 ↗ Jan 200422“All these patients, receiving treatment with oral cyclosporine (Neoral®, Novartis) at 2.5 mg/kg/day, were examined at three-month intervals for a year.” PMID 29454364 ↗ Feb 2018 “Randomization to oral cyclosporine of either Sandimmune or Neoral is also done in a 1:1 ratio.” NCT00000936 ↗ “cyclosporine A (Neoral ®) started from 6 to 8 mg/kg adjusted to C2” NCT01028092 ↗ “cyclosporine (Neoral, Sandimmune and other trade names)” NCT00132691 ↗ “Neoral® capsule containing 25mg or 100mg cyclosporine” NCT01990118 ↗ “cyclosporine (CsA, Sandimmune, Neoral)” NCT00428064 ↗ “Sandimmun (Neoral) dose plus cellcept” NCT04906304 ↗ “Neoral® (Cyclosporine)” NCT00518375 ↗ “Cyclosporine (Neoral)” NCT00419926 ↗ “Cyclosporine(Neoral®)” NCT01817322 ↗ |
| Known as | NeuroSTAT | “Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion” NCT01825044 ↗ |
| Known as | NOVA22007 | “Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis” NCT01751126 ↗ |
| Known as | OTX-CSI | “a single dose of OTX-CSI, a sustained release cyclosporine drug product” NCT04362670 ↗ |
| Known as | PT-CsA | “CRS is usually limited after the administration of post-transplant cyclosporine (PT-CsA) administered on days +3 and +4” NCT04781803 ↗ |
| Known as | Restasis | “The goal of this clinical trial is to compare the administration of 2 drugs, cyclosporine 0.05% (Restasis) and Lifitgrast (Xiidra) before PRK, in reducing the ocular surface...” NCT06624384 ↗28“The purpose of this study is to evaluate the efficacy of 0.05% cyclosporin ophthalmic emulsion (Restasis) in patients with Stevens-Johnson syndrome that have dry eyes by...” NCT01488396 ↗ “This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.” NCT05733624 ↗ “OBJECTIVE: To assess patients' experiences with topical cyclosporine A (tCSA) 0.05% ophthalmic emulsion (Restasis) to treat keratoconjunctivitis sicca (KCS) in a real-world setting.” PMID 16004673 ↗ Jul 2005 “The Effects of Cyclosporin A Emulsion, (Restasis), on the Ocular Surface in Response to Low Humidity Environment in Patients With Dry Eye” NCT02199964 ↗ “Patients receive cyclosporine ophthalmic emulsion (Restasis®) drops in each eye twice daily for up to 1 year after transplant.” NCT00755040 ↗ “All patients were treated with topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California) on twice daily dose” NCT04637633 ↗ “Restasis eye drop(Cyclosporine ophthalmic solution 0.05%) 1 drop twice/day for 12 weeks to both eyes” NCT02461719 ↗ “active comparator (cyclosporine ophthalmic emulsion, 0.05% [Restasis, Allergan Inc., Irvine, CA])” PMID 22607938 ↗ May 2012 “Restasis® is also known as cyclosporine ophthalmic emulsion 0.05% (cyclosporine eye drops).” NCT00824811 ↗ “0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days” NCT03597139 ↗ |
| Known as | RESTASIS (cyclosporine ophthalmic emulsion) 0.05% | “RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%” NCT03597139 ↗ |
| Known as | Restasis eye drop | “Restasis eye drop 0.05% (Cyclosporine)” NCT04384991 ↗ |
| Known as | Sandimmun | “Cyclosporine eye drops 0.5%, was prepared from an oral solution of cyclosporine (Sandimmun®) and combined with castor oil” NCT04376970 ↗2“It is suspected that Cylosporine A (Sandimmun, TM) is less diabetogenic than Tacrolimus (Prograf, TM).” NCT01268995 ↗ |
| Known as | Sandimmun i.v. | “Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days.” NCT00332462 ↗ |
| Known as | Sandimmun Neoral | “All participants received cyclosporine (Sandimmun Neoral) monitored by C0 and blood was collected for analysis of C2 retrospectively.” PMID 19716045 ↗ Sep 20093“Randomised Withdrawal of Mycophenolate Mofetil (CellCept®) or Cyclosporine A (Sandimmun Neoral®)” NCT00148252 ↗ “Cyclosporin A (Sandimmun Neoral® or similar):” NCT02936505 ↗ “Cyclosporine (Sandimmun Neoral)” NCT00488436 ↗ |
| Known as | Sandimmune | “Randomization to oral cyclosporine of either Sandimmune or Neoral is also done in a 1:1 ratio.” NCT00000936 ↗3“cyclosporine (Neoral, Sandimmune and other trade names)” NCT00132691 ↗ “2.5 mg of cyclosporine (Sandimmune, Novartis)” NCT00990795 ↗ “cyclosporine (CsA, Sandimmune, Neoral)” NCT00428064 ↗ |
| Known as | SCAI-001 | “This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.” NCT05733624 ↗ |
| Known as | SHR8028 | “To evaluate the efficacy and safety of SHR8028, a water-free cyclosporine ophthalmic solution, 0.1%, compared with vehicle in Chinese participants with DED.” PMID 38451509 ↗ Apr 2024 |
| Known as | TJO-087 | “Purpose: To compare the efficacy and ocular tolerability of a 0.08% nanoemulsion cyclosporine A (CsA) (TJO-087) once daily versus a conventional 0.05% emulsion CsA twice daily...” PMID 36450107 ↗ Nov 2022 |
| Known as | Vevye | “Vevye (cyclosporine ophthalmic solution) is administered twice daily (BID) in both eyes for the treatment of dry eye disease.” NCT07553455 ↗3“cyclosporine 0.1% dissolved in perfluorobutylpentane (Vevye®)” NCT07368595 ↗ “cyclosporine 0.1% ophthalmic solution (US brand name VEVYE)” PMID 38771801 ↗ May 2024 |
| Action | Inhibit | “CsA is capable of decreasing T cell activation, which in turn may decrease HIV replication.” NCT00000880 ↗ |
| Modality | Other / unclassified | “immunosuppressive calcineurin inhibitor (CNI)” NCT00296296 ↗ |
| Route | Oral | “Administered orally as either sandimmune or neoral at a dose determined by weight.” NCT00000936 ↗ |
| Target | ABCB1 | “The canalicular transport of irinotecan and SN-38G is mediated by ABCC2 (MRP2) and ABCB1 (MDR1) which are both inhibited by ciclosporin.” PMID 23953030 ↗ Aug 2013 |
| Target | ABCC2 | “The canalicular transport of irinotecan and SN-38G is mediated by ABCC2 (MRP2) and ABCB1 (MDR1) which are both inhibited by ciclosporin.” PMID 23953030 ↗ Aug 2013 |